Study of Adaptive Radiotherapy for High-grade Glioma Based on Interfraction MRI
1 other identifier
observational
60
1 country
1
Brief Summary
The changes of target and organs at risk in patients with high-grade glioma during concurrent chemoradiotherapy were evaluated by MRI image between radiotherapy fractions.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2024
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 28, 2023
CompletedStudy Start
First participant enrolled
January 1, 2024
CompletedFirst Posted
Study publicly available on registry
January 11, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
September 30, 2026
ExpectedJanuary 11, 2024
December 1, 2023
1.9 years
November 28, 2023
January 10, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Homogeneity index
HI: Homogeneity index. Dosimetric change
up to 2 weeks
conformity index
CI: conformity index. Dosimetric change
up to 2 weeks
Anatomic change
Dmax Volume
up to 2 weeks
Secondary Outcomes (1)
progression-free survival (PFS)
assessed up to 12 months
Study Arms (1)
Adaptive radiotherapy group
MRI was performed and adaptive radiotherapy was administered at farction10 and fraction 20 during radiotherapy.
Interventions
MRI was performed and adaptive radiotherapy was administered at farction10 and fraction 20 during radiotherapy.
Eligibility Criteria
Patients with high-grade glioma confirmed by pathology in our hospital and treated with standard STUPP regimen.
You may qualify if:
- Age ≥18 years old;
- High-grade glioma was confirmed by pathology after surgery;
- ECOG score 0-2 points;
- Receiving the standard STUPP regimen (i.e. 6 weeks of temozolomide concurrent chemoradiotherapy +6 cycles of temozolomide adjuvant chemotherapy);
- Baseline data available.
You may not qualify if:
- The pathological diagnosis is not clear;
- No synchronous chemotherapy/adjuvant chemotherapy \< 6 cycles;
- There are other malignant tumors;
- Previously radiotherapy to the head;
- Interruption of radiotherapy for more than 5 days;
- Failure to collect baseline data.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
West China Hospital
Chengdu, Sichuan, 610041, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical Professor
Study Record Dates
First Submitted
November 28, 2023
First Posted
January 11, 2024
Study Start
January 1, 2024
Primary Completion
December 1, 2025
Study Completion (Estimated)
September 30, 2026
Last Updated
January 11, 2024
Record last verified: 2023-12